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Abstract
Ischemic stroke (IS) is a major cause ofmortality and disability. However, no reliable prognostic or diagnostic biomarker has been
utilized to date. Here, we have evaluated the serum S100B concentration and miR-602 expression as potential biomarkers for IS.
Fifty-two IS patients and 52 age- and sex-matched healthy volunteers were enrolled. Blood samples were collected from all
patients at the time of admission, 24 and 48 h later, at the time of discharge, and 3 months later. Real-time (RT) PCR was used to
measure the serum level of miR602. We also measured the serum concentration of S100B using ELISA. As compared with
healthy subjects, IS patients had a higher level of serum S100B and lower serum miR-602. ROC curve analyses revealed that
miR-602 (AUC= 0.8168; P < 0.0001) and S100B (AUC= 0.8699; P < 0.0001) had acceptable ability to differentiate between IS
patients from healthy subjects. Furthermore, serum S100B was a reliable predictor of the survival outcome at 3 months (P =
0.021). The expression of miR-602 was significantly higher in patients with bigger NIHSS scores. The lower levels of miR-602
and higher concentration of S100B in the sera of IS patients could be associated with clinically significant diagnostic utilities.
S100B could be also introduced as a reliable prognostic marker for stroke and implemented in future research.
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Introduction
Ischemic stroke (IS) is known as one of the main causes of
mortality and disability in the world [1]. Despite significant
progress having been made in the diagnosis of stroke, namely
in imaging modalities, differentiating it from stroke mimic has
remained a challenging issue. Some studies showed the prog-
nostic and diagnostic roles of biomarkers, including
interleukin-6 (IL-6), D-dimer, and C-reactive protein (CRP)
in ischemic stroke [2–4].
S100 calcium-binding protein B (S100B) is a Ca2+-binding
protein (MW 21 kD), expressed in schwann and astroglial
cells [5]. Several reports have indicated an increased expres-
sion of S100B in IS patients [6]. Serum S100B could be a
promising diagnostic biomarker [7] with prognostic value to
predict the outcome of IS [8, 9].
MicroRNAs (miRNAs) are short (17–25 nucleotides) non-
coding ribonucleic acids which are capable of modulating
several cellular processes including protein expression by
binding to complementary or partially complementary target
sites in the 3′-untranslated regions (3′-UTRs) of messenger
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RNA (mRNA) [10, 11]. Circulating miRNAs in the serum
have been reported to be stable, reproducible, and consistent
among individuals and could be used in clinical settings [10,
12]. There is thriving evidence in favor of the role of miRNAs
in modulating various IS-related biological mechanisms, such
as inflammation, hypertension, atherosclerosis, and plaque
rupture [13]. The expression of miRNAs in IS is also signifi-
cant; the association of selected miRNAs have been demon-
strated with the clinical subgroups of stroke that could be used
as potential biomarkers [14]. The miRBase database (http://
www.mirbase.org) has been used for the identification of
miRNAs in humans and other species. Recent studies have
shown that microRNAs target proteins. We have recently
observed that the target protein of miR-602 was S100B
(http://www.targetscan.org/vert_72/), and the expression of
S100B is regulated by miR-602. Other studies have shown
alterations in the expression of miR-602 [15] and S100B in
stroke patients.
Although S100B has been introduced as an IS biomarker in
limited studies, to the extent of our knowledge, no research
has addressed the diagnostic and prognostic utility of miR-602
which controls the expression of S100B. Therefore, we aimed
to evaluate serum concentrations of miR-602 and its target
protein, S100B in stroke patients, and healthy subjects. We
also assessed the diagnostic and prognostic values of miR-
602 and S100B in IS.
Materials and methods
Study population and sample collection
We recruited fifty-two patients with IS from the Department of
Neurology in Sayyad Shirazi Hospital, Gorgan, Iran. Stroke
was diagnosed in accordance with the neurological deficit
World Health Organization [16], CT scan, MRI, and related
risk factors (history of hypertension, history of diabetes,
smoking, etc.) [17]. We excluded all cases with a history of
malignancy, acute or chronic infectious diseases, autoimmune
disorders, renal or liver failure, and recurrent stroke. We also
enrolled 52 age- and sex-matched healthy volunteers in the
control group. Individuals with a medical family history of
cardiovascular disorders, stroke, kidney or liver failure, and
diabetes were also excluded. The study was approved by the
Committee of Ethics, Golestan University of Medical
Sciences (IR.GOUMS.REC.1395.23). All patients signed a
written informed consent according to the declaration of
Helsinki [6]. All clinical characteristics and laboratory data
are shown in Table 1.
The modified Rankin Scale (mRS), which is a reliable
measure for evaluating the level of dependence or disability
in the activities of individuals incurred a stroke, was evaluated
in all patients and used for further analyses. To examine the
degree of IS, the National Institutes of Health Stroke Scale
(NIHSS) system was used [18]. Accordingly, stroke patients
with NIHSS ≤ 5 were categorized in NIHSS 1 group.
Moderate stroke patients with scores between 6 and 13 were
put in NIHSS 2 group and severe stroke patients with scores ≥
13 were allocated in NIHSS 3 group.
We collected blood samples (serum) at five time points: (A)
0–12 h after stroke (at the time of admission), (B) 24 h after
stroke, (C) 48 h after stroke, (D) at the time of discharge, and
(E) 3 months after stroke. The blood samples were moved to
the research laboratory in the Department of Biochemistry.We
separated sera according to Alatas’s method [19] and trans-
ferred into two separate microtubes, kept at − 70 °C until
analysis. The rest of the separated sera were immediately proc-
essed for the total RNA extraction.
RNA extraction and quantitative real-time PCR
The isolation of total RNA was performed using TRIzol LS
reagent (Invitrogen, Carlsbad, USA) from separated sera of
all individuals following established protocols [20]. The quality
and quantity of extracted RNAwere assessed using spectropho-
tometry (Picodrop, UK). A specific miR-602 and an endoge-
nous U6 stem-loop control primer were used for the reverse
transcription of 1 μg total RNA to cDNA based on the manu-
facturer’s guidelines of the thermo scientific kit (K1622, San
Jose, CA, USA). Afterwards, cDNAwas stored at − 20 °C.
Quantitative real-time PCR was performed using a fast
real-time PCR system (lightcycler96, Roche, USA) using a
RealQ Plus Master Mix Green (Ampliqon, Denmark). The
final reaction volume was 20 μL containing miR-602 or U6
RT reaction product (3 μl), specific forward primer [miR-602
(5′-AGGACACGGGAGACAGC-3′) and U6 (5′-AAGG
ATGACACGCAAATTC-3′)] (1 μl), reverse primer (5′-
GAGCAGGGTCCGAGGT-3′) (1 μl), RealQ Plus Master
Mix Green (10 μl), and DEPC water (5 μl). A 96-well plate
format was used with the following protocol: 95 °C for
15 min, followed by 40 cycles of 95 °C for 30 s, 60 °C for
30 s, and 72 °C for 30 s. Eventually, the relative miR-602 level
was normalized to the expression of the endogenous control
U6 for each single sample in triplicates and was calculated
using the 2−Δct method.
S100B ELISA assay
A commercially available ELISA kit (Elabscience Houston,
Texas, USA) was used to measure serum S100B according to
the protocols. Chromate 4300 (Biotek, USA) was applied to
examine the optical densities (ODs) of all samples at the
wavelength of 450 nm versus the reference wavelength of
630 nm. All of the experiments for each single sample were
conducted in duplicates and the results were reported as pico-
grams of S100B per ml.
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Fig. 1 The serum concentration of miR-602 and S100B levels at the time
of admission. miR-602 is downregulated in IS patients (a), while S100B
is expressed in higher quantities (b). The calculations of the expression
levels for miR-602 were conducted by 2−ΔCt method. To compare the
means between two groups, Students’ T test was used (patients 52,
healthy subjects 52). Statistics on each scattered plot demonstrates
mean ± SD. Level of significant P values were 0.05
Table 1 Demographic data and
laboratory characteristics of
patients with ischemic stroke and
healthy controls
Patients with IS (n = 52) Healthy controls (n = 52) P value
Age (year) 69.38 ± 11.24 69.40 ± 11.10 0.993
BS (mg/dL) 153.64 ± 47.23 110.96 ± 18.26 < 0.001
BP (mmHg) 144.34 ± 55.32 86.54 ± 3.71 < 0.001
Sex Male 34 (65.38%) 34 (65.38%) 0.999
Female 18 (34.61%) 18 (34.61%)
MRS score ≤ 2 18(34.61%) - < 0.0001
> 2 34(65.38%) -
NIHSS 7.588 ± 1.132 - -
PT (s) 12.90 ± 0.36 12.58 ± 0.50 0.009
PTT (s) 33.54 ± 5.58 30.45 ± 2.41 0.017
WBC )10^3/uL) 8.93 ± 3.36 6.55 ± 1.15 0.002
RBC (10^6/uL) 4.65 ± 0.61 5.18 ± 0.49 0.001
MCV (fL) 13.41 ± 1.73 14.32 ± 1.02 0.024
MCH (pg) 86.02 ± 7.96 86.10 ± 3.68 0.963
Hb (g/dL) 28.68 ± 3.27 28.84 ± 1.51 0.820
PLT (10^3/uL) 200.69 ± 55.03 232.97 ± 35.23 0.014
Fig. 2 The serum concentration of miR-602 and S100B in 5 different
time points. miR-602 serum levels did not alter (a), while S100B serum
levels did not change significantly in all 5 time points among IS patients
(b). The calculations of the expression levels for miR-602 were
conducted by 2−ΔCt method. One-way ANOVA and Tukey’s post-test
or Kruskal–Wallis and Dunn–Bonferroni post-test were used to evaluate
the differences between themeans of various groups. (patients 52, healthy
subjects 52). Bar charts show mean ± SD for each value. Level of
significant P values were 0.05
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Statistical analysis
Receiver operator characteristic (ROC) curve analysis was
performed to determine the diagnostic utility of miR-602
and S100B. In order tomodel the relationship between a scalar
response and one or more explanatory variables (or indepen-
dent variables), linear regression was used. Two-wayANOVA
or Kruskal–Wallis and relevant post hoc tests were conducted
to compare the means between more than two groups.
Kaplan–Meier survival analyses were performed after follow-
ing the outcome of the disease (death or survival) to inspect
the prognostic values of the selected variables in IS patients,
and relevant plots were drawn. We used means and standard
deviation to illustrate quantitative statistics, numbers, and per-
centages to represent qualitative data. In order to compare the
demographic variables including age, blood pressure, and sex,
T test and chi-square were used. The P values beneath 0.05
were granted as statistically significant. We evaluated the time
course for the expression of the putative biomarkers, miR-602
and S100B, at five time points.
Results
The expression of miR-602 and S100B at time
of admission
We found that serum miR-602 was lower in the IS patients
compared with the normal controls (P < 0.0001) (Fig. 1a), and
that serum S100B was significantly higher in patients in com-
parison with the healthy controls (P < 0.0001) (Fig. 1b).
Serum levels of both S100B and miR-602 did not alter signif-
icantly at different time points until the end of the follow-up
schedule (Fig. 2).
S100B and miR-602 as suitable diagnostic markers
The area under the curve (AUC) for the expression of miR-
602 was 0.8168 (95% CI 0.7281–0.9054; P < 0.0001). The
cut-off point was set at the fold change level of 0.1290 with
the sensitivity of 78.85% (95% CI 65.30–88.94), the specific-
ity of 84.62% (95% CI 71.92–93.12), and likelihood ratio
(LR) of 5.125 (Fig. 3a). Similarly, the calculated AUC for
S100B was 0.8699 (95% CI 0.7981–0.9417; P < 0.0001).
The cut-off value was set at the optimum level of 39.99 ng/ml
with the sensitivity of 76.47% (95% CI 62.51–87.21), the
Fig. 3 ROC curve analyses. Area under the curve (AUC) for miR-602
was 0.8168 (P < 0.0001). Setting the cut-off value (blue arrows) at 0.1290
gave a sensitivity of 78.85%, specificity of 84.62%, and likelihood ratio
(LR) of 5.125 (a). AUC for S100B was 0.8699 (P < 0.0001). The
optimum cut-off value at the level of 39.99 gave a sensitivity of
76.47%, specificity of 82.69%, and likelihood ratio (LR) of 4.192 (b).
All values are the expression levels at the time of zero (initial referring to
the hospital)
Fig. 4 Survival analyses. IS patients were subdivided into two categories
of high and low expression on the basis of the optimum cut-off points of
suggested biomarkers. Log-rank test results showed that miR-602 was not
able to predict the outcome (death) of the disease after 90 days of follow-
up (a), while the lower expression of S100B was associated with a good
prognosis of the disease (b)
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specificity of 82.69% (95% CI 69.67–91.77), and likelihood
ratio (LR) of 4.192 (Fig. 3b).
S100B and miR-602 were reliable predictors of IS
prognosis
The levels of both biomarkers were subdivided into two cat-
egories of low and high levels based on the optimum cut-off
points derived fromROC curve analyses. Log-rank test results
revealed that miR-602 was not capable of predicting the out-
come (death;N, 26) of IS (P = 0.6863) (Fig. 4a), while the low
levels of S100B were associated with good prognosis in IS
patients (P = 0.0212) (Fig. 4b). We also found a negative but
weak correlation between the miR-602 and S100B upon ad-
mission (rs = − 0.264, P = 0.007).
miR-602 was reduced in IS patients
with the maximum modified Rankin Scale
In order to measure the expression of selected variables and
determine the association of S100B and miR-602 with the
disability status of IS patients, a modified Rankin Scale
(mRS scoring ( was utilized. Although not statistically signif-
icant, the expression of miR-602 was decreased among IS
patients with the maximum disability (mRS = 5). However,
S100B was not varied between different groups of mRS
(Fig. 5).
The overexpression of miR-602 in IS patients
with higher NIHSS scores
Patients were categorized into three different groups accord-
ing to their NIHSS scores, as abovementioned. The expression
of miR-602 was significantly higher in patients in NIHSS 2
(P < 0.05) and NIHSS 3 (P < 0.01) subgroups (Fig. 6a).
However, no significant difference was shown between vari-
ous subgroups of NIHSS regarding the serum concentration of
S100B (Fig. 6b).
Discussion
A reliable diagnosis of IS at early stages could reduce the
complications of the disease and increase the survival rate
[20]. However, there remains a lack of a reliable diagnostic
Fig. 5 Alterations of S100B and miR-602 after 3 months of follow-up in
different categories of mRS. miR-602 was downregulated in IS patients
of the MRS 5 category (a), while no remarkable change was observed in
the expression of S100B between 5 groups ofMRS (b). IS patients falling
in the 6th category of mRS had passed away and no record of S100B or
miR-602 was available. One-way ANOVA and Tukey’s post-test or
Kruskal–Wallis and Dunn–Bonferroni post-test were used to evaluate
the differences between the means of various groups. Bar charts show
mean ± SD for each value. Level of significant P values were 0.05
Fig. 6 The expression of S100B and miR-602 in different groups of
NIHSS at the time of admission. miR-602 was significantly
overexpressed in NIHSS subgroups with higher scores (a), while
S100B was not altered in different subgroups of NIHSS (b). Kruskal–
Wallis and Dunn–Bonferroni post-test were used to evaluate the
differences between the means of various groups. Bar charts show
mean ± SD for each value. Level of significant P values were 0.05
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and prognostic marker for IS, with just the current reliance on
clinical examinations and imaging. There are two main types
of biomarkers: exposure biomarkers which are utilized in risk
prediction, and disease biomarkers in screening, diagnosis,
and monitoring of disease progression [21, 22]. Some studies
have previously indicated that biomarkers of IS include
neuron-specific enolase (NSE), myelin basic protein (MBP),
matrixmetallopeptidase 9 (MMP-9), glial fibrillary acidic pro-
tein (GFAP), interleukin 6 (IL-6), and D-Dimer [23].
However, none of these biomarkers have gained sufficient
support to be included in the routine laboratory repertoire.
Recently, there has been rising evidence that serum S100B
may be a unique biomarker for the diagnosis of IS [24]. Serum
protein S100B has been also introduced a diagnostic biomark-
er for distinguishing posterior circulation stroke from Vertigo
of nonvascular causes [25]. The mechanisms leading to the
increased levels of serum S100B are unknown [26].
Moreover, numerous researches have diversely shown alter-
ations of microRNAs in the central nervous system following
injury and their involvement in apoptosis, inflammatory neu-
ronal death, and oxidative stress. Recently, microRNAs
especially circulating microRNAs have been introduced
as sensitive biomarkers for brain damage [5, 6, 27].
Therefore, circulating microRNAs could be applicable
biomarkers for the diagnosis of IS and monitoring the
outcome of the disease. Here, we evaluated the expres-
sion of circulating miR-602 and its potential target
(S100B) as appropriate diagnostic and prognostic
markers for ischemic stroke.
We found that serum miR-602 levels in IS patients were
less than their counterparts in healthy controls. However, no
indicative difference in serum miR-602 expression was ob-
served between different time points of follow-up. To the ex-
tent of our knowledge, this is the first report of the serummiR-
602 after 3 months of follow-up following IS. We also found
that the serum level of S100B was increased in IS patients
compared with the normal controls. S100B levels were not
essentially changed at the five time intervals after stroke.
Other studies have also reported that serum S100B is signifi-
cantly higher in IS and intracranial hemorrhage patients [5, 22,
23]. The results by ROC curve analyses implied that miR-602
and S100B had admissible sensitivities for the diagnosis of
ischemic stroke in patients. They could be favorable serum
biomarkers for the diagnosis of ischemic stroke in association
with the previous reports [28, 29].
Kaplan–Meier plots (log-rank) analysis of survival rates
revealed that miR-602 was not able to predict the outcome
(death) of IS, while serum S100B was a powerful prognostic
marker for IS in our study. Although miR-602 is a prognostic
biomarker in other diseases such as glioblastoma and pancre-
atic ductal adenocarcinoma [22, 30], other studies have dem-
onstrated that S100B is of prognostic value in IS [31, 32].
Several studies have demonstrated that elevator S100B serum
levels could be negatively correlated with IS, suggesting that
higher serum levels of S100B could lead to more serious con-
dition and worse prognoses for IS patients [33]. We also dem-
onstrated a negative but weak correlation between the serum
expression of miR-602 and S100B upon admission, which
may indicate the regulatory effects of miR-602 on the expres-
sion of S100B. Here, we have evaluated the alterations of
miR-602 and S100B at different time points of mRS after
3 months of following up and found that miR-602 was
expressed in lower levels among IS patients with the maxi-
mum disability.
The NIHSS is a 15-item scale that measures the standards
and criteria for basic neurologic examination and focuses on
aspects most related to stroke [34]. The NIHSS provides an
ordinal, nonlinear measure of acute stroke-related impair-
ments by assigning values to various aspects of the function
of the brain [6]. Most stroke patients with NIHSS ≤ 5 (NIHSS
1) were discharged. Moderate stroke patients with scores be-
tween 6 and 13 (NIHSS 2) went to acute rehabilitation, and
severe stroke patients with scores ≥ 13 (NIHSS 3) required
nursing facility (NF) placement [34]. In contrast to the previ-
ous findings which have demonstrated a correlation between
National Institutes of Health Stroke Scale (NIHSS) at admis-
sion time and plasma S100B levels [6], we showed no signif-
icant correlation, which could be due to the limited samples
size of our study. Although we expected trending changes in
the expression of S100B among different groups of NIHSS,
limited sample size could confine the conclusion and more
compelling data is needed to confirm or reject our findings.
Moreover, we found a significant correlation between miR-
602 and NIHSS; miR-602 was overexpressed in higher
NIHSS scores. However, the overexpression of miR-602 in
patient groups with moderate and higher NIHSS could not
thoroughly reflect the severity of the disease due to
the lack of sample size in the NIHSS 2 (6 IS patients)
and 3 (11 IS patients) groups and further investigations
are needed in this regard.
In conclusion, we aimed to investigate the diagnostic and
prognostic accuracy of miR-602 and S100B as novel bio-
markers for IS. We found that serum miR-602 was lower in
patients with IS, and serum S100B was higher in these pa-
tients, which may be associated with clinically significant di-
agnostic utilities. Although miR-602 was not capable of
predicting the outcome of IS, the level of S100B in the sera
could be introduced as a powerful prognostic marker for
stroke. It will be useful in future studies to establish whether
these findings are specific to IS, or whether there are differ-
ences for hemorrhagic stroke.
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